Meet Dr. GPCR Summit Partners
- Click to Explore -
Innate Proximity: Utilizing the Inherent Physicality of Receptor Interactions for Drug Development
Thursday, 09/16/ 2021 @ 10:00 AM - EST
- Dr. Ajay Yekkirala -
- CSO & Co-Founder Blue Therapeutics -
- Waltham, Massachusetts, USA -
Abstract
A fundamental tenet of biology is that receptors interact. It is these interactions that provide context to pharmacology. There is an “innate proximity” to such interactions – whether they are constitutive (oligomerization of RTKs or GPCRs for instance) or transient (such as the serine protease TMPRSS2 cleaving ACE2 increasing SARS-CoV-2 viral entry) – that can be utilized to design molecules with better medicinal properties. I present some examples in the opioid and dopamine receptor interactomes that will delineate the advantages to targeting such interactions in pain and other neurological disorders.
About Dr. Ajay Yekkirala
Ajay Yekkirala is co-founder & CSO of Blue Therapeutics, a platform company focused on utilizing the power of receptor-interactomicsTM to develop novel therapies. He is the co-inventor of Blue's core technology and has over 15 years of experience in GPCR and ion channel drug discovery and development. Ajay completed his doctoral studies with ACS hall of fame chemist, Dr. Philip Portoghese, at the University of Minnesota and postdoctoral training under renowned pain neurobiologist Clifford Woolf at Harvard. He has authored several papers published in high-impact, peer-reviewed journals, including book chapters and invited reviews. He is also a recipient of the Bacaner Research Award from the Minnesota Medical Foundation.
Dr. Ajay Yekkirala on the web
Meet Dr. GPCR Summit Partners
- Click to Explore -
